Сложности диагностики и особенности клинического течения анапластического рака щитовидной железы. Клинический случай

Статья посвящена клиническому наблюдению местно-распространенного метастатического анапластического рака щитовидной железы. Освещены сложности инструментальной и лабораторной диагностики данной патологии, а также роль молекулярной диагностики в поиске высокоэффективного лечения.

1. Ragazzi M., Ciarrocchi A., Sancisi V. et al. Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int J Endocrinol 2014;2014:790834. DOI: 10.1155/2014/790834

2. De Lellis R.A., Lloyd R.V. , Heitz P.U., Eng C. Pathology and genetics of tumors of endocrine organs. IARC, Lyon, France, 2004.

3. Untch B.R., Olson J.A. Jr. Anaplastic thyroid carcinoma, thyroid lymphoma, and metastasis to thyroid. Surg Oncol Clin N Am 2006;15(3):661-79. DOI: 10.1016/j.soc.2006.05.006

4. Nikiforov Y.E., Nikiforova M.N. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011;7(10):569-80. DOI: 10.1038/nrendo.2011.142

5. Smallridge R.C., Ain K.B., Asa S.L. et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012;22(11):1104-39. DOI: 10.1089/thy.2012.0302

6. Sherman S.I. Anaplastic carcinoma: clinical aspects. In: Thyroid cancer: a comprehensive guide to clinical management. Ed. by L. Wartofsky, D. Van Nostrand. 2nd edn. Totowa: Humana Press, 2006. Pp. 629-632.

7. Asa S.L., Bedard Y.C. Fine-needle aspiration cytology and histopathology. In: Thyroid cancer: diagnosis and treatment. Ed. by O.H. Clark, S. Noguchi. St. Louis: Quality Medical Publishing, 2000. Pp. 105-126.

8. Are C., Shaha A.R. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13(4):453-64. DOI: 10.1245/ASO.2006.05.042

9. McIver B., Hay I.D., Giuffrida D.F. et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001;130(6):1028-34. DOI: 10.1067/msy.2001.118266

10. De Crevoisier R., Baudin E., Bachelot A. et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 2004;60(4):1137-43. DOI: 10.1016/j.ijrobp.2004.05.032

11. Mohebati A., Dilorenzo M., Palmer F. et al. Anaplastic thyroid carcinoma: a 25-year single-institution experience. Ann Surg Oncol 2014;21(5):1665-70. DOI: 10.1245/s10434-014-3545-5

12. Keutgen X.M., Sadowski S.M., Kebebew E. Management of anaplastic thyroid cancer. Gland Surg 2015;4(1):44-51. DOI: 10.3978/j.issn.2227-684X.2014.12.02

13. Paraiso K.H., Fedorenko I.V., Cantini L.P. et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010;102(12):1724-30. DOI: 10.1038/sj.bjc.6605714

14. Flaherty K.T., Infante J.R., Daud A. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367(18):1694-703. DOI: 10.1056/NEJMoa1210093

15. U.S. Food and Drug Administration. FDA approves dabrafenib plus trametinib for anaplastic thyroid cancer with BRAF V600E mutation. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenib-plus-trametinib-anaplastic-thyroid-cancer-braf-v600e-mutation

16. Capdevila J., Wirth L.J., Ernst T. et al. PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol 2020;38(23):2620-7. DOI: 10.1200/JCO.19.02727

17. Bastman J.J., Serracino H.S., Zhu Y. et al. Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 2016;101(7):2863-73. DOI: 10.1210/jc.2015-4227.